The Pharmacy Times® Chronic Obstructive Pulmonary Disease (COPD) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Continuing education for pharmacists.
The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.
High Levels of Ozone, Wood Burning Linked to Chronic Obstructive Pulmonary Disease Among Smokers, Nonsmokers
Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.
The tool, which works by attaching a small sensor to the patient’s inhaler, collects data on medication use and sends medication reminders, progress reports, and disease insights to the patient’s smartphone or hub.
Each November, members of the chronic obstructive pulmonary disease (COPD) community come together to focus on increasing awareness of the respiratory condition.
Results from the safety and efficacy trial of revefenacin (REV) demonstrated that the drug had a safety profile similar to foremoterol (FOR). In addition, patients with COPD in the suboptimal peak inspiratory flow rate trial (sPIFR) showed lower weight, BMI, and lung function in comparison to patients with optimal peak inspiratory flow rate (oPIFR) in a second study.
Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.
A researcher at the Washington University School of Medicine in St.Louis has received close to $7.5 million in total funding for research towards development of stem cell-based treatments for chronic pulmonary disease (COPD), asthma, and other disorders.
Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.
The Phase III ETHOS trial for AstraZeneca's budesonide, glycopyrronium and formoterol fumarate, 320/14.4/9.6mcg (Breztri Aerosphere) combination therapy has demonstrated positive results for patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Published in Clinical Rehabilitation, investigators found that breathing techniques commonly utilized in yoga may be an effective adjunct intervention for individuals with COPD.